Objective To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura(iTTP).Methods This study analyzed the effic...Objective To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura(iTTP).Methods This study analyzed the efficacy and adverse reactions of four patients with relapsed iTTP who were treated with a combination of obinutuzumab and glucocorticoids to assess the effectiveness and safety of the treatment.Results All four patients had a history of multiple relapses and had previously undergone treatment with rituximab and bortezomib.Three patients exhibited additiona1l autoantibodiesF.ollowingthecombined therapy,all patients achieved clinical remission,with ADAMTS13 activity returning to normal levels and inhibitors testing negative.During a median follow-up period of 11 months(range:3-17 months),all patients maintained sustained remission.No severe adverse eventswerereported during treatment or follow-up.Conclusion The combination of obinutuzumab and glucocorticoid-based therapy is effective and safe for treating relapsed iTTP.展开更多
文摘Objective To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura(iTTP).Methods This study analyzed the efficacy and adverse reactions of four patients with relapsed iTTP who were treated with a combination of obinutuzumab and glucocorticoids to assess the effectiveness and safety of the treatment.Results All four patients had a history of multiple relapses and had previously undergone treatment with rituximab and bortezomib.Three patients exhibited additiona1l autoantibodiesF.ollowingthecombined therapy,all patients achieved clinical remission,with ADAMTS13 activity returning to normal levels and inhibitors testing negative.During a median follow-up period of 11 months(range:3-17 months),all patients maintained sustained remission.No severe adverse eventswerereported during treatment or follow-up.Conclusion The combination of obinutuzumab and glucocorticoid-based therapy is effective and safe for treating relapsed iTTP.
